IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) has earned an average rating of “Hold” from the six brokerages that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $2.53.
A number of brokerages have recently commented on IPCI. HC Wainwright set a $3.00 target price on shares of IntelliPharmaCeutics Intl and gave the company a “buy” rating in a report on Monday. Maxim Group set a $2.00 target price on shares of IntelliPharmaCeutics Intl and gave the company a “buy” rating in a report on Friday. Finally, Zacks Investment Research cut shares of IntelliPharmaCeutics Intl from a “hold” rating to a “sell” rating in a report on Wednesday, January 17th.
A hedge fund recently raised its stake in IntelliPharmaCeutics Intl stock. Advisor Group Inc. boosted its position in IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) by 57.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,409 shares of the company’s stock after buying an additional 17,342 shares during the period. Advisor Group Inc. owned approximately 0.16% of IntelliPharmaCeutics Intl worth $100,000 as of its most recent SEC filing. 3.28% of the stock is owned by institutional investors and hedge funds.
About IntelliPharmaCeutics Intl
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.